Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that the gross proceeds from the sale of the shares will be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon Therapeutics. In addition, Harpoon Therapeutics has granted the underwriters in the offering a 30-day option to purchase up to 882,352 additional shares of common stock at the public offering price. The offering is expected to close on January 11, 2021, subject to customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering with a life sciences capital markets led by Bay Area partners Brian Cuneo and John Williams with associates Michelle Lu, Taimi Jacobson and Melinda Vanderburg. Advice was also provided on FDA regulatory matters by Washington, DC partner Elizabeth Richards with associates Barrett Tenbarge and Lacey Henry; on healthcare regulatory matters by Bay Area counsel Betty Pang; on tax matters by Bay Area partner Grace Lee with associate Gregory Conyers; on technology transactions matters by Bay Area partner Chris Hazuka with associate Peggy Ni; and on benefits and compensation matters by Bay Area partner Jay Metz with associate Brianna Stellpflug.